- AbbVie Migraine Career Catalyst Award™ contest winners
shared inspiring stories and professional goals, showcasing their
triumphs over the challenges of living with migraine
- AbbVie, a leader in migraine treatment, is committed to
addressing the impact of migraine in the workplace
- Nearly 40 million Americans are living with migraine, a
debilitating neurological disease, and are more likely to call in
sick due to symptoms associated with
migraine.1-2
NORTH
CHICAGO, Ill., Nov. 14,
2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today
announced 20 winners of the inaugural AbbVie Migraine Career
Catalyst Award™ contest, a first-of-its-kind contest designed to
support the career aspirations of people living with migraine. The
winning entries were selected from short essay, video, and audio
clip submissions highlighting entrants' experiences living with
migraine, their career aspirations, and how this award could help
support their future success.
The 20 winners represent a diverse range of professions,
including engineers, scientists, teachers, park service employees,
animal shelter workers, artists, and musicians. Beyond their
professional roles, these individuals exemplify a rich diversity of
life experiences—they are parents, grandparents, students, and
caregivers who balance a variety of responsibilities while managing
the challenges that migraine symptoms may present. Many have
options from the significant advances in treatment in recent years,
providing further opportunities to develop in their careers.
"Migraine impacted my life in ways that I hadn't anticipated. I
spent most of my career working in state parks, outdoor recreation,
and tourism. However, the demands of public service combined with
the unpredictability of migraine have made life incredibly
challenging," said Melissa from Davis,
WV, 2024 AbbVie Migraine Career Catalyst Award contest
winner. "This award will allow me to create a mentorship program in
my small town and share my experience and knowledge in outdoor
recreation with the next generation, ensuring that they are better
equipped to navigate the challenges of their careers with or
without migraine."
People living with migraine often face unique challenges in
managing their careers1 but these winners exemplify
resilience and determination in pursuing their educational and
career goals. The AbbVie Migraine Career Catalyst Award™ recognizes
their strength and aims to provide the necessary support to help
them thrive in their chosen fields, highlighting that their
ambitions extend well beyond the impact of migraine.
"Migraine can significantly affect an individual's career
trajectory and long-term potential. Despite these challenges, the
recipients of the inaugural AbbVie Migraine Career Catalyst Award
have shared their remarkable determination to overcome
disease-related obstacles as they work toward their professional
aspirations," said Jag Dosanjh, senior vice president, AbbVie, and
president, neuroscience and eye care. "As the only company with
three treatment options that collectively address the entire
spectrum of migraine, we have a deep understanding of the
challenges that people living with migraine can face in the
workplace, and we're proud to support these individuals as they
lead lives that transcend obstacles often imposed by the impact of
the disease."
Nearly 40 million Americans are living with migraine, a
debilitating neurological disease, and are more likely to call in
sick due to symptoms associated with migraine.1-2 Over
113 million work days are lost each year in the U.S. due to
migraine and related symptoms.1 It is the second leading
cause of disability worldwide3 with symptoms like severe
headaches, nausea, and sensitivity to light often disrupting
day-to-day activities,2 making it difficult to maintain
consistent performance at work or school.1
Additional 2024 Migraine Career Catalyst Award contest
winners on their experience:
- "As someone living with chronic migraine, it never fails to
surprise me how often this condition is misunderstood. My migraine
has allowed me to experience a greater depth of compassion and
empathy for others, and has led to my passion for women's health
and social equity," said Anjali from Washington, D.C. "[This award] will
help me pursue law school so that I can dedicate my career towards
advocating for healthcare providers and patients."
- "As a mom of four with a fifth on the way, there's so much
going on that I don't have time for my head to hurt. I work from
home, but balancing work, my kids, and migraine is a daily
struggle," said Laura from Mount Juliet,
TN. "Migraine doesn't just affect me – it affects my whole
family. [This award] means so much to me. I can finally set up a
real working space to allow me to work more comfortably and
efficiently, reducing the strain that contributes to my migraine in
the first place."
- "I've been battling migraine for over a decade. I work in video
production where bright lights are everywhere – that's a real
challenge," said Walter from Lexington,
KY. "I will use the award to get more training and acoustic
foam treatment for my workspace to create a quiet work environment.
This isn't just about me. This is about showing that with the right
support, people with migraine can thrive in their careers."
To see the full list of winners, visit:
https://www.migrainecareercatalyst.com/.
About AbbVie in Migraine
Migraine is more than a headache.4 Impacting 1 billion
people around the world, migraine is a neurological disease that
causes pain and debilitating symptoms.4-8 Our science is
helping healthcare providers to care for people across the spectrum
of migraine. Through education and partnerships with the migraine
community, we strive to help patients, and their families navigate
barriers to care, access effective treatments and reduce the impact
of migraine on their lives. We are dedicated to the pursuit of
MIGRAINE FREEDOM™.
AbbVie is the only company with three prescription treatments
designed to meet patient needs across the full spectrum of migraine
to help patients living with this debilitating disease. At AbbVie,
we are committed to empowering people living with migraine disease.
We advance science that enables healthcare providers to care for
people impacted across the spectrum of migraine.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines
that solve serious health issues today and address the medical
challenges of tomorrow. We strive to have a remarkable impact on
people's lives across several key therapeutic areas – immunology,
oncology, neuroscience, and eye care – and products and services in
our Allergan Aesthetics portfolio. For more information about
AbbVie, please visit us at www.abbvie.com. Follow @abbvie
on LinkedIn, Facebook, Instagram, X (formerly
Twitter), and YouTube.
About the AbbVie Migraine Career Catalyst Award™
Contest
AbbVie, a leader in migraine care, recognizes the
unique challenges people with migraine face in their professional
lives. The AbbVie Migraine Career Catalyst Award™ contest was
created to support individuals affected by migraine in pursuing
their career aspirations and managing the limitations that migraine
can often impose.
Eligible U.S. residents aged 18 and older who have encountered
work-related migraine challenges were invited to enter to win the
contest by submitting an entry between June
3, 2024, at 12:00 p.m. ET and
September 3, 2024, at 12:00 p.m. ET. Entrants were asked to submit a
short essay (up to 3,000 characters), a video (up to 3 minutes), or
an audio clip (up to 3 minutes) describing their migraine
experiences, career goals, and how the award could help them
professionally. From the entries received, twenty (20) winners were
selected to receive up to $2,500.00
each to support their career pursuits. Judging was held between
September 3, 2024, at 12:01 p.m. ET and September 25, 2024, at 12:00 p.m. ET, conducted by an AbbVie-appointed
panel of communications, medical, and marketing professionals.
Entries were evaluated based on the following three criteria:
Originality and Language Style, Clarity, and Relevance to the
Contest Theme.
Information about entering the 2025 contest will be available at
www.migrainecareercatalyst.com in June
2025.
Forward-Looking Statements
Some statements in
this news release are, or may be considered, forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995. The words "believe," "expect," "anticipate," "project"
and similar expressions and uses of future or conditional verbs,
generally identify forward-looking statements. AbbVie cautions that
these forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially
from those expressed or implied in the forward-looking statements.
Such risks and uncertainties include, but are not limited to,
challenges to intellectual property, competition from other
products, difficulties inherent in the research and development
process, adverse litigation or government action, and changes to
laws and regulations applicable to our industry. Additional
information about the economic, competitive, governmental,
technological and other factors that may affect AbbVie's operations
is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual
Report on Form 10-K, which has been filed with the Securities and
Exchange Commission, as updated by its subsequent Quarterly Reports
on Form 10-Q. AbbVie undertakes no obligation, and specifically
declines, to release publicly any revisions to forward-looking
statements as a result of subsequent events or developments, except
as required by law.
US-NEUM-240098
References:
- Adams AM, Serrano D, et al. Perceived effect of migraine on
career and finances: results of the chronic migraine epidemiology
and outcomes (CaMEO). ClinicalTrials.gov identifier: NCT01648530.
Updated January 29, 2015. Accessed
January 19, 2024.
clinicaltrials.gov/ct2/show/NCT01648530.
- American Migraine Foundation. What is migraine? January 21, 2021. Accessed January 31, 2024.
https://americanmigrainefoundation.org/resource-library/what-is-migraine/
- World Health Organization. Migraine and other headache
disorders. March 6, 2024. Accessed
October 1, 2024.
https://www.who.int/news-room/fact-sheets/detail/headache-disorders
- Headache Classification Committee of the International Headache
Society (IHS). The international classification of headache
disorders, 3rd edition. Cephalalgia.
2018;38:1-211.
- Amiri P, Kazeminasab S, Nejadghaderi SA, Mohammadinasab R,
Pourfathi H, Araj-Khodaei M, Sullman MJM, Kolahi AA, Safiri S.
Migraine: a review on its history, global epidemiology, risk
factors, and comorbidities. Front Neurol. 2022 Feb
23;12:800605. doi: 10.3389/fneur.2021.800605. PMID: 35281991;
PMCID: PMC8904749.
- Steiner, T. J., Stovner, L. J., Vos, T., Jensen, R., &
Katsarava, Z. Migraine is first cause of disability in under 50s:
will health politicians now take notice? J Headache Pain.
2018;19:17.
- AbbVie. Data on File: ABVRRTI73750.
- Katsarava Z, Buse DC, Manack AN, Lipton RB. Defining the
differences between episodic migraine and chronic migraine. Curr
Pain Headache Rep. 2012;16:86-92.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/abbvie-awards-20-individuals-living-with-migraine-to-support-career-aspirations-302305019.html
SOURCE AbbVie